Table 1.
Characteristics of included studies
| Author year | Group | N of Pati Carv/Cont |
Administration of intervention | Time of outcome assessment | Drop Carv/Cont | ITT |
|---|---|---|---|---|---|---|
| Banares 199916 | Carv/Prop | 14/14 | Carv: 25 mg four times a day orally Prop: 0.15 mg/kg intravenously followed by a continuous infusion of 0.2 mg/kg |
60 min | 0/0 | No |
| Banares 200227 | Carv/Prop | 26/25 | Carv: 31±4 mg orally Prop: 73±10 mg orally |
11.1±4.1 weeks | 2/3 | No |
| De 200223 | Carv/Prop | 18/18 | Carv: start at 25 mg four times a day orally followed by 6.25 mg twice daily Prop: start at 80 mg four times a day orally followed by 40 mg twice daily |
90 min; 7 days |
I/2 | No |
| Hobolth 201210 | Carv/Prop | 24/23 | Carv: start at 3.125 mg twice daily, followed by 14±7 mg/day orally Prop: start at 40 mg twice daily, orally followed by 122±64 mg/day |
90 min; 92.7±13.6 days |
3/6 | No |
| Lin 200422 | Carv/Prop+ISMN | 11/11 | Carv: 25 mg, four times a day, orally Prop: 40 mg plus ISMN (20 mg), four times a day, orally |
90 min | 0/0 | No |
| Lo 201229 | Carv/Nado+ ISMN | 61/60 | Carv: 10.4±2.2 mg/day orally Nado: 45±13 mg+20 mg ISMNs/day orally |
30 months | 5/6 | Yes |
| Mo 201431 | Carv/Prop | 48/48 | Carv: started at 12.5 mg, four times a day orally then adjusted according to the BP, HR Prop: started at 10 mg, three times a day, orally then adjusted according to the BP, HR |
7 days | 0/0 | No |
| Shah 201425 | Carv/EVL | 82/86 | Carv: 6.25 mg four times a day for 1 week, 6.25 mg twice daily thereafter orally EVL: underwent EVL within 48 h of randomisation, repeated every 3 weeks |
13 months | 2/0 | Yes |
| Silkauskaite 201324 | Carv/Nebi | 10/10 | Carv: 25 mg four times a day orally Nebi: 5 mg four times aday orally |
60 min; 14 days |
1/2 | No |
| Sohn 201330 | Carv/Prop | 50/49 | Carv: 11.6±2.2 mg/day orally Prop: 153.5±100.2 mg/day orally |
6 weeks | 8/11 | Yes |
| Stanley 201426 | Carv/EVL | 33/31 | Carv: 6.25 mg four times a day for the first week, 12.5 mg/day thereafter orally EVL: underwent EVL within 1 week, then repeated every 2 weeks |
26.4 months | 14/11 | Yes |
| Tripathi 200928 | Carv/EVL | 77/75 | Carv: started at 6.25 mg four times a day for the first week; 12.5 mg thereafter orally EVL: underwent EVL every 2 weeks |
26 months | 25/23 | Yes |
BP, blood pressure; Carv, carvedilol; Cont, control; EVL, endoscopic variceal band ligation; ISMN, isosorbide-5-mononitrate; ITT, intention-to-treat analysis; Nado, nadolol; Nebi, nebivolol; Pati, patients; Prop, propranolol.